Department of Inpatient Pharmacy, Long Beach Memorial Medical Center, Long Beach, CA, USA.
Ann Pharmacother. 2013 Feb;47(2):e12. doi: 10.1345/aph.1R646. Epub 2013 Jan 29.
To report a case of foodborne botulism and subsequent use of the investigational heptavalent botulism antitoxin (H-BAT).
A 60-year-old man was hospitalized with blurred vision, diplopia, and dysarthria. On hospital day 2, the patient was transferred to the intensive care unit for progressive fatigable weakness with ptosis, dysphagia, dysarthria, and nausea. Secondary to worsening respiratory distress, the patient was intubated and placed on a ventilator. The patient could open his eyes only with assistance but still had normal strength in all extremities. H-BAT was administered 48 hours after presentation for possible botulism. The patient then revealed that he consumed home-canned corn several days prior to admission. On hospital day 8, botulinum neurotoxin was confirmed in the patient's serum and the home-canned corn. The patient slowly regained muscle strength and was discharged to a long-term acute care facility on hospital day 22.
Foodborne botulism is caused by a neurotoxin from Clostridium botulinum and usually occurs after the consumption of improperly prepared home-canned food. Botulism is characterized by symmetrical descending paralysis that may progress to respiratory arrest. The standard confirmatory test for botulism is a mouse bioassay to prove the presence of botulinum neurotoxin. Outside of supportive care, the treatment options for botulism are limited. Individuals with botulism often require intensive care unit monitoring and potentially ventilatory support. H-BAT, the only treatment available for botulism in patients older than 1 year, is a purified and despeciated equine-derived immunoglobulin active against all known botulinum neurotoxins. H-BAT's despeciation significantly reduces the risk of hypersensitivity reactions, anaphylaxis, and serum sickness.
In a confirmed case of foodborne botulism treated with H-BAT, the patient tolerated H-BAT and did not develop any hypersensitivity reactions or serum sickness.
报告 1 例食源性肉毒中毒病例及随后使用研究性七价肉毒杆菌抗毒素(H-BAT)的情况。
一名 60 岁男性因视物模糊、复视和构音障碍住院。入院第 2 天,患者因进行性易疲劳性无力转至重症监护病房,表现为眼睑下垂、吞咽困难、构音障碍和恶心。由于呼吸窘迫恶化,患者行气管插管并接呼吸机辅助通气。患者仅在协助下才能睁开眼睛,但四肢仍有正常肌力。患者在出现症状后 48 小时内使用 H-BAT,可能是为了治疗肉毒中毒。患者随后透露,他在入院前几天食用了自制罐装玉米。入院第 8 天,患者血清和自制罐装玉米中均证实存在肉毒神经毒素。患者的肌肉力量逐渐恢复,入院第 22 天出院至长期急性护理机构。
食源性肉毒中毒是由 C. botulinum 的神经毒素引起的,通常发生在食用不当制备的家庭自制罐装食品后。肉毒中毒的特征是对称的进行性弛缓性瘫痪,可能进展为呼吸停止。肉毒中毒的标准确认试验是小鼠生物测定法,以证明存在肉毒神经毒素。除了支持性治疗外,肉毒中毒的治疗选择有限。肉毒中毒患者通常需要重症监护病房监测和潜在的通气支持。H-BAT 是一种纯化的、去特异性的马源性免疫球蛋白,可对抗所有已知的肉毒神经毒素,是 1 岁以上肉毒中毒患者唯一可用的治疗药物。H-BAT 的去特异性显著降低了过敏反应、过敏反应和血清病的风险。
在接受 H-BAT 治疗的确诊食源性肉毒中毒病例中,患者耐受了 H-BAT,未发生任何过敏反应或血清病。